Bank of America’s Aegerion Pharmaceuticals AEGR Stock Holding History

Bank of America’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-65,900	Closed	-$1.38M	–	7917
2014 Q4	$1.38M	Buy	65,900 +33,100	+101%	+$834K	﹤0.01%	3748
2014 Q3	$1.09M	Buy	32,800 +31,000	+1,722%	+$962K	﹤0.01%	3918
2014 Q2	$58K	Sell	1,800 -4,500	-71%	-$168K	﹤0.01%	6554
2014 Q1	$291K	Buy	6,300 +5,800	+1,160%	+$340K	﹤0.01%	5103
2013 Q4	$35K	Sell	500 -1,800	-78%	-$138K	﹤0.01%	6778
2013 Q3	$197K	Sell	2,300 -500	-18%	-$42.4K	﹤0.01%	5467
2013 Q2	$177K	Buy	+2,800	New	+$149K	﹤0.01%	5738

Bank of America's AEGR Position: Q4 2016 in Review

Bank of America sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2016, closing a stake of 26,434 shares — an estimated $79K sold.

Bank of America first reported a position in AEGR in Q2 2013 and held it in 14 quarters. The position peaked at $43.2M in Q3 2014. 0 funds tracked by Wall St. Rank hold AEGR as of Q4 2016.

Bank of America reported no remaining Aegerion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Bank of America sold 26,434 Aegerion Pharmaceuticals shares in Q4 2016, an estimated $79K.
Bank of America first reported a position in Aegerion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Bank of America's Aegerion Pharmaceuticals position peaked at $43.2M in Q3 2014.
0 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2016.

Based on Bank of America's 13F filing for Q4 2016, filed 14 Feb 2017.